Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQQ4 | ISIN: SE0015658570 | Ticker-Symbol: 3EE0
Frankfurt
27.06.25 | 08:07
0,137 Euro
+1,04 % +0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KANCERA AB Chart 1 Jahr
5-Tage-Chart
KANCERA AB 5-Tage-Chart

Aktuelle News zur KANCERA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Kancera AB: Kancera reports positive top-line results from the KANDOVA study310Kancera AB (publ) (Kancera) today reports the top-line results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian...
► Artikel lesen
KANCERA Aktie jetzt für 0€ handeln
05.06.Kancera AB: Kancera reports positive outcome of pre-IND meeting with FDA49Kancera AB (publ) (Kancera) today reports that it has completed a successful pre-IND meeting with the FDA and received positive feedback on the planned clinical development program for KAND567 in ST-elevation...
► Artikel lesen
23.05.Kancera AB: Interim Report First Quarter 2025, January 1 - March 3175The period in brief - financial summary for the first quarter 2025Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 11,1 million (SEK 11,4 million).Operating loss for...
► Artikel lesen
20.05.Kancera AB: Kancera provides an update on the collaboration with Recardio Inc. and the company's clinical development program112In connection with the upcoming financial interim report for the first quarter 2025, Kancera AB (publ) (Kancera) provides an update on the ongoing collaboration with Recardio Inc. and the company's...
► Artikel lesen
08.04.Kancera AB: Kancera reports Last Patient Last Visit in the KANDOVA study120Kancera AB (publ) reports that the last patient has completed the last visit in the ongoing phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer. Kancera reports that the...
► Artikel lesen
07.03.Kancera AB: Kancera announces intention to change company name to Novakand Pharma117Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company's strategic decision to focus on cardiovascular diseases. "The current...
► Artikel lesen
07.03.Kancera AB: Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145132Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145Recardio's phase...
► Artikel lesen
21.02.Kancera AB: Interim Report Fourth Quarter 2024, October 1 - December 3199The period in brief - financial summary for the fourth quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 8,5 million (SEK 17,1 million).Operating loss for...
► Artikel lesen
15.11.24Kancera AB: Interim Report Third Quarter 2024, July 1 - September 30221The period in brief - financial summary for the third quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 10,2 million (SEK 9,2 million).Operating loss for the...
► Artikel lesen
23.08.24Kancera AB: Interim Report Second Quarter 2024, April 1 - June 30126The period in brief - financial summary for the second quarter 2024Net sales amounted to SEK 0 million (SEK 0 million).R&D expenses amounted to SEK 9,7 million (SEK 16,5 million).Operating loss for...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1